Shopping Cart
- Remove All
Your shopping cart is currently empty
RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $41 | In Stock | |
| 5 mg | $111 | In Stock | |
| 10 mg | $180 | In Stock | |
| 25 mg | $342 | In Stock | |
| 50 mg | $496 | In Stock | |
| 100 mg | $680 | In Stock | |
| 200 mg | $896 | In Stock |
| Description | RSH-7 is a potent dual inhibitor of BTK and FLT3, with IC50s of 47 and 12 nM, respectively.RSH-7 has antiproliferative and antitumor activities, inducing apoptosis and inhibiting BTK and FLT3 signaling. |
| Targets&IC50 | BTK:47 nM, FLT3:12 nM |
| In vitro | RSH-7 (1-1000 nM; 72 h) demonstrates antiproliferative activities against Jeko-1, MV-4-11, Molt4, and K562 cells with IC50 values of 17 nM, 3 nM, 11 nM, and 930 nM, respectively.[1] It dose-dependently reduces the expression of p-BTK (TYR223), p-PLCγ(Tyr1217), p-FLT3 (Tyr589), and p-STAT5 (TYR694), and triggers apoptosis while upregulating BAX, p53, and cleaved caspase 3 in Jeko-1 cells.[1] |
| In vivo | RSH-7 (25, 50 mg/kg; i.p.; daily for 16 days; Female NOD/SCID mice) suppressed tumor growth in a dose-dependent manner, with TGI values of 66.95% and 79.78% at doses of 25 and 50 mg/kg, respectively.[1] |
| Molecular Weight | 436.49 |
| Formula | C22H25FN8O |
| Cas No. | 2764609-97-2 |
| Smiles | N(C1=C(C(NN)=O)C=CC=C1)C2=NC(NC3=CC=C(C=C3)N4CCN(C)CC4)=NC=C2F |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 75 mg/mL (171.83 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.